UBS Group’s Spero Therapeutics SPRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.04K | Sell |
3,009
-113,438
| -97% | -$269K | ﹤0.01% | 8629 |
|
|
2025
Q4 | $271K | Buy |
116,447
+89,346
| +330% | +$207K | ﹤0.01% | 6421 |
|
|
2025
Q3 | $51K | Buy |
27,101
+18,907
| +231% | +$41.6K | ﹤0.01% | 7553 |
|
|
2025
Q2 | $23.8K | Buy |
8,194
+5,368
| +190% | +$7.72K | ﹤0.01% | 8322 |
|
|
2025
Q1 | $2.04K | Buy |
2,826
+2,685
| +1,904% | +$2.27K | ﹤0.01% | 9410 |
|
|
2024
Q4 | $145 | Sell |
141
-17,388
| -99% | -$20.7K | ﹤0.01% | 9604 |
|
|
2024
Q3 | $23.5K | Buy |
17,529
+17,198
| +5,196% | +$23.1K | ﹤0.01% | 7275 |
|
|
2024
Q2 | $430 | Sell |
331
-5,397
| -94% | -$8.14K | ﹤0.01% | 8924 |
|
|
2024
Q1 | $9.85K | Buy |
5,728
+5,399
| +1,641% | +$8.46K | ﹤0.01% | 7263 |
|
|
2023
Q4 | $484 | Sell |
329
-26,806
| -99% | -$32K | ﹤0.01% | 8639 |
|
|
2023
Q3 | $32.8K | Buy |
27,135
+64
| +0.2% | +$89 | ﹤0.01% | 6550 |
|
|
2023
Q2 | $39.3K | Sell |
27,071
-14,452
| -35% | -$24.7K | ﹤0.01% | 6595 |
|
|
2023
Q1 | $60.2K | Sell |
41,523
-4,159
| -9% | -$6.96K | ﹤0.01% | 6310 |
|
|
2022
Q4 | $79K | Buy |
45,682
+22,774
| +99% | +$42.5K | ﹤0.01% | 6324 |
|
|
2022
Q3 | $46K | Buy |
22,908
+22,153
| +2,934% | +$22K | ﹤0.01% | 6435 |
|
|
2022
Q2 | $1K | Hold |
755
| – | – | ﹤0.01% | 9955 |
|
|
2022
Q1 | $7K | Sell |
755
-32,327
| -98% | -$331K | ﹤0.01% | 8842 |
|
|
2021
Q4 | $529K | Buy |
33,082
+4,260
| +15% | +$67.7K | ﹤0.01% | 4934 |
|
|
2021
Q3 | $530K | Buy |
28,822
+26,929
| +1,423% | +$432K | ﹤0.01% | 4698 |
|
|
2021
Q2 | $27K | Sell |
1,893
-29,134
| -94% | -$407K | ﹤0.01% | 7044 |
|
|
2021
Q1 | $456K | Buy |
31,027
+16,680
| +116% | +$294K | ﹤0.01% | 4945 |
|
|
2020
Q4 | $278K | Buy |
14,347
+13,847
| +2,769% | +$216K | ﹤0.01% | 5022 |
|
|
2020
Q3 | $6K | Sell |
500
-5,452
| -92% | -$64.5K | ﹤0.01% | 7235 |
|
|
2020
Q2 | $80K | Sell |
5,952
-3,041
| -34% | -$34.1K | ﹤0.01% | 5482 |
|
|
2020
Q1 | $73K | Sell |
8,993
-5,274
| -37% | -$46.5K | ﹤0.01% | 5536 |
|
|
2019
Q4 | $137K | Buy |
14,267
+3,216
| +29% | +$34.7K | ﹤0.01% | 5835 |
|
|
2019
Q3 | $117K | Sell |
11,051
-751
| -6% | -$7.91K | ﹤0.01% | 5676 |
|
|
2019
Q2 | $136K | Buy |
+11,802
| New | +$142K | ﹤0.01% | 5172 |
|
|
2019
Q1 | – | Sell |
-3,200
| Closed | -$20K | – | 8137 |
|
|
2018
Q4 | $20K | Buy |
3,200
+841
| +36% | +$6.81K | ﹤0.01% | 6795 |
|
|
2018
Q3 | $25K | Buy |
2,359
+1,414
| +150% | +$16.4K | ﹤0.01% | 6674 |
|
|
2018
Q2 | $13K | Buy |
945
+449
| +91% | +$5.75K | ﹤0.01% | 6999 |
|
|
2018
Q1 | $7K | Buy |
496
+368
| +288% | +$4.46K | ﹤0.01% | 7086 |
|
|
2017
Q4 | $1K | Buy |
+128
| New | +$1.57K | ﹤0.01% | 7726 |
|
Other funds holding SPRO
GP
P
VCM
AI
AFM
UBS Group's SPRO Position: Q1 2026 in Review
UBS Group reduced its Spero Therapeutics (SPRO) stake by 97% in Q1 2026, selling an estimated $269K and leaving 3,009 shares worth $7.04K. The position accounts for ﹤0.01% of the portfolio, ranked #8629.
UBS Group first reported a position in SPRO in Q4 2017 and has held it in 33 quarters since. The position peaked at $530K in Q3 2021. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.
- UBS Group held 3,009 shares of Spero Therapeutics worth $7.04K as of Q1 2026.
- UBS Group sold 113,438 Spero Therapeutics shares in Q1 2026, an estimated $269K.
- Spero Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8629 holding.
- UBS Group first reported a position in Spero Therapeutics in Q4 2017 and has held it in 33 quarters since.
- UBS Group's Spero Therapeutics position peaked at $530K in Q3 2021.
- 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.